Despite recent advances, graft-versus-host disease (GVHD) remains the main cause of treatment failure for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Tacrolimus (FK506) has been increasingly used in place of cyclosporine (CSP), and several studies have shown that FK506 reduces the incidence of acute GVHD more effectively than does CSP. However, no survival benefits have been demonstrated, and no established consensus exists on the choice of these immunosuppressive agents. To compare a CSPbased and an FK506-based regimen, we performed a large-scale retrospective study by using the data of 1935 patients who underwent HSCT from HLA-identical sibling donors (SIB-HSCT) and 777 patients who underwent HSCT from unrelated donors (UD-HSCT). For patients undergoing UD-HSCT, FK506 significantly reduced the risk of acute GVHD and treatment-related mortality (TRM) without an increase in relapse, thus improving overall survival (OS) (hazard ratio (HR): 2.20, 95% confidence interval (CI): 1.60-3.04, Po0.0001 for grade II-IV acute GVHD; HR: 1.81, 95% CI: 1.32-2.48, P ¼ 0.0003 for TRM; HR: 1.62, 95% CI: 1.23-2.14, P ¼ 0.0007 for OS). This superiority of FK506 was not observed in SIB-HSCT cases. These findings indicate that the use of FK506 instead of CSP for GVHD prophylaxis is beneficial for patients undergoing UD-HSCT.
Summary:
Despite recent advances, graft-versus-host disease (GVHD) remains the main cause of treatment failure for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Tacrolimus (FK506) has been increasingly used in place of cyclosporine (CSP), and several studies have shown that FK506 reduces the incidence of acute GVHD more effectively than does CSP. However, no survival benefits have been demonstrated, and no established consensus exists on the choice of these immunosuppressive agents. To compare a CSPbased and an FK506-based regimen, we performed a large-scale retrospective study by using the data of 1935 patients who underwent HSCT from HLA-identical sibling donors (SIB-HSCT) and 777 patients who underwent HSCT from unrelated donors (UD-HSCT). For patients undergoing UD-HSCT, FK506 significantly reduced the risk of acute GVHD and treatment-related mortality (TRM) without an increase in relapse, thus improving overall survival (OS) (hazard ratio (HR): 2.20, 95% confidence interval (CI): 1.60-3.04, Po0.0001 for grade II-IV acute GVHD; HR: 1.81, 95% CI: 1.32-2.48, P ¼ 0.0003 for TRM; HR: 1.62, 95% CI: 1.23-2.14, P ¼ 0.0007 for OS). This superiority of FK506 was not observed in SIB-HSCT cases. These findings indicate that the use of FK506 instead of CSP for GVHD prophylaxis is beneficial for patients undergoing UD-HSCT. Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality for patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), and its control is essential for the success of the modality. Over the past decade, many advances have been made in terms of pharmacological immunosuppression for GVHD prevention. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Cyclosporine (CSP) is the most commonly used agent, and the combination of CSP and short-term methotrexate (MTX) has been adopted as standard treatment. [1] [2] [3] [4] [5] [6] Tacrolimus (FK506) has a similar mechanism of action as CSP, and also inhibits T-cell activation by blocking the phosphatase activity of calcineurin. 15, 16 This drug was introduced into clinical studies for GVHD prophylaxis in the mid 1990s. [8] [9] [10] [11] [12] [13] [14] Although several studies have shown a lower incidence of acute GVHD as compared with that obtained with CSP, no survival benefits have been demonstrated. [12] [13] [14] Despite its adverse effects, GVHD is also known to be beneficial because it can prevent relapse of malignant diseases through the graft-versus-tumor (GVT) reaction. Large retrospective studies have shown a lower relapse rate (RR) for patients who developed acute and chronic GVHD, [17] [18] [19] [20] [21] leading to concern that increasing the intensity of GVHD prophylaxis may increase the risk of relapse. For these reasons, not only the incidence of GVHD but also its influence on patient outcomes, including overall survival (OS), treatment-related mortality (TRM) and relapse, should be evaluated. We therefore performed a large-scale retrospective study comparing a CSP-based regimen and an FK506-based regimen by using the registry data of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). A total of 1935 patients who underwent HSCT from HLA-identical sibling donors (SIB-HSCT) and 777 patients who underwent HSCT from unrelated donors (UD-HSCT) were analyzed.
Patients and methods

Patients
The study population consisted of 2712 adult patients with hematological disorders, 16 years of age or older, who were reported to the JSHCT as having undergone their first SIB-HSCT or UD-HSCT with GVHD prophylaxis consisting of either CSP or FK506 between January 1996 and December 2001. Patients who had received nonmyeloablative stem cell transplantation or cord blood transplantation were excluded, as were those having been conditioned with antithymocyte globulin or having received a manipulated graft. Sibling pairs who were matched by serology for HLA-A, -B and -DR loci were considered to be HLA identical. DNA typing for HLA-DRB1 alleles was performed for most unrelated pairs, and that for HLA-A and -B alleles was performed in recent cases at the attending physician's discretion. For unrelated pairs, HLA compatibility was judged on the basis of available data reported to the registry. Information on surviving patients was updated annually. This study was approved by the Committee for Nationwide Survey Data Management of the JSHCT.
Statistical analysis
The primary end point of this study was to assess the effect of GVHD prophylaxis regimens on the development of grade II-IV acute GVHD. The secondary end points were to assess the effect of the regimens on the development of extensive chronic GVHD, relapse, TRM and OS. SIB-HSCT and UD-HSCT were analyzed separately. OS was defined as the time from the day of transplant to death or last follow-up. Relapse was defined as hematological recurrence, and only those with malignant diseases were evaluated. Patients never achieving complete remission (CR) after transplant were considered to have had a recurrence on day 0. TRM was defined as death while in continuous CR. Acute and chronic GVHD were evaluated according to the standard criteria. 22, 23 Those who died before engraftment were excluded from the analysis of acute GVHD. For the analysis of chronic GVHD, only those who survived 100 days post transplant without relapse were included. The Cox proportional hazards regression model was used to evaluate the effect of age, sex, graft source, HLA compatibility, disease status, conditioning regimens and GVHD prophylaxis (CSP-based regimen or FK506-based regimen). The use of MTX was not included in the analysis because more than 95% of patients received it. Factors with P-values of less than 0.10 for univariate analysis were included in the subsequent multivariate Cox model, while GVHD prophylaxis was included in each model. Hazard ratio (HR) was calculated in conjunction with a 95% confidence interval (CI). For disease status, those with hematological malignancies in CR at the time of transplant, in chronic phase of chronic myeloid leukemia (CML), with refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) of myelodysplastic syndrome (MDS), and with nonmalignant diseases were defined as being at standard risk. All those with other disease entities were defined as being at advanced risk. For assessment of the effect of graft source, patients receiving both BM and PB stem cells (2% of SIB-HSCT) were excluded. Distributions of patient characteristics in the CSP and FK506 groups were compared by using the w 2 test for categorical variables, and the Wilcoxon rank-sum test for continuous variables. Kaplan-Meier analyses were performed to estimate the probability of OS, TRM and GVHD. For relapse and TRM, each was used as a censored event for the other. Differences between the curves were compared by means of the log-rank test. Stat View 5.0 (SAS Institute Inc., Cary, NC, USA) was used for all statistical analyses.
Results
Patient characteristics
Patient characteristics are summarized in Table 1 . SIB-HSCT was administered to 1935 patients, and UD-HSCT to 777 patients. The median follow-up period for surviving patients was 1073 days. The proportion of patients receiving an FK506-based regimen was 3% for SIB-HSCT and 25% for UD-HSCT. The distributions of patient characteristics in the CSP and FK506 groups were comparable except for sex in the SIB-HSCT group, while for UD-HSCT, patients receiving FK506 were more likely to have received a transplant from HLA-mismatched donors and to have been conditioned with total-body irradiation (TBI)-based regimens. Since allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated donors has not been approved in Japan, the graft source for UD-HSCT consisted entirely of bone marrow.
Acute GVHD
The proportions of patients developing grade II-IV acute GVHD are shown in Figure 1 . For SIB-HSCT, there was no significant difference in the incidence between the CSP and FK506 groups (37.5 and 32.9% at 100 days, P ¼ 0.5374; Figure 1a) . In contrast, a higher rate of occurrence of grade II-IV acute GVHD was seen in patients receiving a CSP-based regimen than in those receiving an FK506-based regimen for UD-HSCT (57.8 and 36.4% at 100 days, Po0.0001; Figure 1b) . Multivariate analysis confirmed that an FK506-based regimen reduced the risk of grade II-IV acute GVHD for UD-HSCT more than did a CSP-based regimen (HR: 2.20, 95% CI: 1.60-3.04, Po0.0001; Table 2 ). The development of grade III-IV acute GVHD was also impacted favorably by the use of FK506 for UD-HSCT (HR: 2.10, 95% CI: 1.32-3.34, P ¼ 0.0018), but not for SIB-HSCT (P ¼ 0.9789).
Chronic GVHD
The proportions of patients developing extensive chronic GVHD are shown in Figure 2 . The probability at 3 years was 32.6% for the CSP group and 12.2% for the FK506 group in the case of SIB-HSCT (P ¼ 0.0220; Figure 2a ), and this difference reached statistical significance in multivariate analysis (HR: 3.69, 95% CI: 1.18-11.53, P ¼ 0.0247; Table 3 ). For UD-HSCT, no significant difference was observed between the two groups in the incidence of extensive chronic GVHD (35.0 and 37.6% at 3 years, P ¼ 0.6618, Figure 2b ; P ¼ 0.5350 in multivariate analysis; Table 3 ).
Outcomes
The Kaplan-Meier estimates of OS were comparable for the FK506 and CSP groups in the case of SIB-HSCT with 3-year survival rates of 57.9 and 58.1% (P ¼ 0.7379; Figure 3a ). In the case of UD-HSCT, on the other hand, the actuarial survival rate was higher for the FK506 group than for the CSP group with respective probabilities of 55.1 and 48.7% at 3 years (P ¼ 0.0073; Figure 3b ). Multivariate analysis demonstrated that an FK506-based regimen resulted in a significantly better survival after UD-HSCT (HR: 1.62, 95% CI: 1.23-2.14, P ¼ 0.0007; Table 4 ). The risk of relapse did not differ significantly for the CSP and FK506 groups in the case of either SIB-HSCT or UD-HSCT (P ¼ 0.8965 and 0.3699, respectively, in multivariate analysis). The risk of TRM was significantly higher for the CSP group than for the FK506 group in the case of UD-HSCT (P ¼ 0.0046; Figure 4b . HR: 1.81, 95% CI: 1.32-2.48, Po0.0001; Table 5 ), but not in that of SIB-HSCT (P ¼ 0.7466; Figure 4a . P ¼ 0.4416 in multivariate analysis; Table 5 ).
Discussion
Our study results indicate that the influence of the two GVHD prophylaxis regimens on the study end points varies depending on the donor type. FK506 provided better prophylaxis against acute GVHD than CSP for UD-HSCT, but not for SIB-HSCT. On the other hand, there was a lower incidence of chronic GVHD in the FK506 group for SIB-HSCT, but not for UD-HSCT. Patients who received FK506 had a significant reduction of TRM without an increase in relapse, which resulted in better OS for the FK506 than for the CSP group following UD-HSCT, but no difference was observed for survival after SIB-HSCT.
Owing to its strong immunosuppressive activity, FK506 has been increasingly used for GVHD prophylaxis in allogeneic HSCT. To date, results of three randomized trials comparing CSP and FK506 have been reported, and all of them showed a significantly lower incidence of acute GVHD for patients receiving FK506. [12] [13] [14] Our result for UD-HSCT agreed with those of the previous studies. However, among patients undergoing SIB-HSCT, the difference did not reach statistical significance. Although it should be remembered that the risk of severe acute GVHD is lower for Japanese than for Caucasian populations as reported previously, [24] [25] [26] a subgroup analysis of a Japanese study presented by Hiraoka et al 14 showed that the incidence of grade II-IV acute GVHD was significantly lower following the FK506 prophylaxis than after treatment with CSP for SIB-HSCT (13.3 and 41.3% at 100 days, P ¼ 0.015 by log-rank test). The reported incidence for CSP was almost equivalent to that observed in our study, while the incidence for FK506 prophylaxis in the Hiraoka study was rather low. This discrepancy may be partly explained by the fact that the latter study used a relatively high dose of FK506 with starting dose of 0.05 mg/kg/day and the targeted concentration range was determined as 20-25 ng/ ml, although it is not definitive. Some investigators have reported no relationship between FK506 levels and the occurrence of acute GVHD. 27 The findings for the development of extensive chronic GVHD were unexpected, because the superiority of FK506 was shown in the case of patients receiving SIB-HSCT, who were at lower risk, but not for patients receiving UD-HSCT. Although the number of patients receiving FK506 for SIB-HSCT was not large enough to draw a conclusion, we speculate that the lower incidence of acute GVHD in the FK506 group for UD-HSCT might affect the subsequent development of chronic GVHD as a result of more rapid tapering off of the agents or less frequent immunosuppressive intervention, thus offsetting the beneficial effect of FK506. While GVHD is the major life-threatening complication of allogeneic HSCT, it is accompanied by the GVT effect, which protects patients from relapse. [17] [18] [19] [20] [21] Assessment of relapse and survival is therefore also important. Previous randomized studies comparing CSP and FK506 did not show any survival benefits of FK506 despite a reduction in the incidence of acute GVHD. [12] [13] [14] Instead, a study of SIB-HSCT by Ratanatharathorn et al 12 found that the patients treated with CSP had a significantly better OS than those treated with FK506. It has been pointed out that the inferiority of FK506 in that study was due to differences in the underlying risk factors for death. 28 All the same, there have been no reports of survival benefits of FK506 over CSP. Some of our findings are consistent with the results of those studies, regarding that FK506 provides better prophylaxis against acute GVHD than CSP, and that a lower incidence of acute GVHD is not accompanied with an increasing risk of relapse. This study also suggests that FK506 significantly reduces the risk of TRM, and improves OS when intended for patients undergoing UD-HSCT. In the previous studies of UD-HSCT, the survival advantage of FK506 over CSP was not significant; however, OS in the FK506 arms appeared slightly better. 13, 14 Although cautions should be taken due to the retrospective nature of this study, the results presented here were based on the multivariate analyses including a large number of patients.
In conclusion, this nationwide survey conducted in Japan indicates that the use of FK506 instead of CSP is beneficial not only for the prevention of GVHD but also for survival of patients undergoing UD-HSCT. 
